PANAMA, XELAVIRI & VALENTINO: gene expression signature for risk stratification in mCRC

Marco Germani, MD, FRCP, University of Pisa, Pisa, Italy, discusses the identification and validation of a prognostic mRNA expression signature in metastatic colorectal cancer (mCRC) using data from the PANAMA (NCT01991873), XELAVIRI (NCT01249638), and VALENTINO (NCT02476045) trials. A three-gene signature (VAV3, TDGF1, AGRN) was identified, which can stratify patients into low-risk groups with improved progression-free survival (PFS) and overall survival (OS), regardless of anti-EGFR or anti-VEGF exposure. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.